Sprint Bioscience AB Cash Flow Statement

Financials in millions SEK. Fiscal year is January - December.

Millions SEK. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	91.74	-18.28	-0.44	-60.17	-25.08
Depreciation & Amortization	1.07	0.96	0.45	0.62	0.59
Other Operating Activities	-	-	-	-	-0.06
Change in Accounts Receivable	6.02	-4.25	-2.55	-0.09	-0.1
Change in Accounts Payable	-1.04	-0.23	2.02	0.84	-0.43
Change in Other Net Operating Assets	-14.26	-1.56	23.39	-0.25	-15.04
Operating Cash Flow	83.53	-23.36	22.87	-59.05	-40.12
Capital Expenditures	-0.09	-1.3	-2.45	-	-2.71
Investment in Securities	0.04	-	-	-	-
Investing Cash Flow	-0.05	-1.3	-2.45	-	-2.71
Short-Term Debt Issued	-	-	-	-	10
Total Debt Issued	-	-	-	-	10
Net Debt Issued (Repaid)	-	-	-	-	10
Issuance of Common Stock	23.45	-	0.02	22.41	88.8
Other Financing Activities	-5.28	-0.23	-	-4.51	-12.41
Financing Cash Flow	18.17	-0.23	0.02	17.9	86.39
Net Cash Flow	101.65	-24.88	20.44	-41.15	43.57
Free Cash Flow	83.44	-24.65	20.42	-59.05	-42.82
Free Cash Flow Margin	49.77%	-37.27%	39.50%	-71149.40%	-122.26%
Free Cash Flow Per Share	0.90	-0.35	0.29	-1.40	-1.49
Cash Interest Paid	-	0.04	0.39	0.11	0.37
Levered Free Cash Flow	52.51	-18.16	19.99	-36.81	-23.87
Unlevered Free Cash Flow	52.51	-18.14	19.99	-36.81	-23.7
Change in Working Capital	-9.28	-6.04	22.86	0.5	-15.57

Source: S&P Global Market Intelligence. Standard template. Financial Sources.